Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (July 2013)
37 slides from Clearpoint Neuro's investor presentation, Jul 9, 2013
Slide 1: MRI Interventions Investor Presentation July 2013
MRI INTERVENTIONS ™ Ticker: MRIC Investor Presentation July 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain matters in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “antic
Slide 3: MRI Interventions, Inc. (MRIC)
MRI Interventions, Inc. (MRIC)
Slide 4: Company Highlights
Company Highlights lization, insid patier Large Market 2.2 million treatmen Platform | mrerdouey Opportunity scuiineenia Therapies Commercial Traction FDA-cleared, CE-n dinterventions for MRI-guided minimally invash
Slide 5: Next Gen Platforms Have Been Developed for Other Specialties
Next Gen Platforms Have Been Developed for Other Specialties and Revolutionized Those Fields . Orthopedics } F aa Sse Abdominal ff Cardiac Surgery Opensurgerybased | Opensurgerybased | Open-heartsurgery Opensurgeryand | Past on pre-surgical on pre-surgical based on pre- stereotactic MIS. images imag
Slide 6: Next Gen Neuro Platform Requires Real-time, High Resolution Visualization
Next Gen Neuro Platform Requires Real-time, High Resolution Visualization Without ClearPoint, minimally invasive procedures are performed “blind” Conventional Stereotactic POINT Procedure system No visualization
Slide 7: ClearPoint Neuro Intervention System
MRI INTERVENTIONS ™ ClearPoint Neuro Intervention System
Slide 8: ClearPoint Procedure Overview
ClearPoint Procedure Overview Target Selection & Entry Planni ENTRY PLANNING
Slide 9: ClearPoint Procedure Overview
ClearPoint Procedure Overview SmartFrame® Trajectory Guide | Trajectory Alignment & Device Insertion
Slide 10: ClearPoint Procedure Overview
ClearPoint Procedure Overview | Delivery of Neurological Therapy Drug Delivery* Asleep DBS Laser Ablation? + The SmartFlow® cannula is presently FDA-cleared for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during intracranial procedures. Deliv
Slide 11: Enabling Transformative Change in Delivery of Neuro Therapies
Enabling Transformative Change in Delivery of Neuro Therapies WITHOUT CLEARPOINT WITH CLEARPOINT Drug Delivery Injecting drugs blind, often misses target Deep Brain Stimulation Inserting DBS leads blind, often requires awake patient Destruction of Diseased Tissue Can be highly invasive surgical proc
Slide 12: The ClearPoint Difference
The ClearPoint Difference No direct visualization, Performedin an operating room Patient often must be awake for their own brain surgery Long procedures— Can be up to 8 hours Complex procedure, requires extensive training Poor economics for hospital and physician ClearPoint is a win-win-win Direct,
Slide 13: ClearPoint Revenue Model
ClearPoint Revenue Model BUSINESS MODEL — RAZOR / RAZORBLADE * ClearPoint Hardware/Software: $130,000 ASP (paid upfront or over time) ClearPoint Disposables: $7,300 ASP per procedure with strong margins Generate recurring revenue from the sale of disposables Procedures covered by existing reimbursem
Slide 14: Gateway for the Delivery of Therapeutics to the Brain
Gateway for the Delivery of Therapeutics to the Brain Delivery of Drugs, Gene Therapy, Stem Cells Placement of DBS Leads GATEWAY Destruction of Diseased Tissue TRAE Indes Derick Wiveston Prekesatlon |
Slide 15: Value of ClearPoint Gateway — Patient Populations
Value of ClearPoint Gateway — Patient Populations US Patient Populations Neuro Disorder Parkinson's Disease Epilepsy Brain Tumor ocp Major Depression Dystonia Alzheimer's Huntington’s 1,500,000 2,300,000 200,000 3,300,000 6,000,000 250,000 5,400,000 30,000 ant 150,000 250,000 | 30,000 100,000 1,200,
Slide 16: Value of ClearPoint Gateway - Market Opportunity
Value of ClearPoint Gateway - Market Opportunity (~ Total ClearPoint US market opportunity > $16 billion - Parkinson’s DBS sub-segment alone represents US market opportunity of $1.1 billion - Epilepsy Focal Ablation sub-segment alone < represents US market opportunity of $1.8 billion ClearPoint OUS
Slide 17: ClearPoint's Unique Opportunity in Drug Delivery
ClearPoint’s Unique Opportunity in Drug Delivery Delivery of Drugs to the Brain Presents Special Challenges - Systemic delivery (pills, shots, IV) of almost all drugs blocked by Blood Brain Barrier (BBB) - BBB blocks 98% of small molecules and virtually 100% of large molecules Direct Injection witho
Slide 18: Compelling Business Model in Drug Delivery
Compelling Business Model in Drug Delivery MRIC partners with drug company/researchers - MRIC provides ClearPoint, a unique delivery platform - Drug company provides promising CNS drug candidate (FDA approval still needed) - ClearPoint becomes the delivery platform for the drug in trials and beyond
Slide 19: Building the Value of the ClearPoint Gateway
MRI INTERVENTIONS ™ Building the Value of the ClearPoint Gateway
Slide 20: Building on a Sturdy Foundation
Building on a Sturdy Foundation Leading industry partners, academic institutions, and clinicians support MRIC technology and its application across multiple specialties. INDUSTRY PARTNERS CLINICIAN ADVISORS SIEMENS #BrainLAB Boston, Scientific UNIVERSITY RESEARCH (fT 4 THE Dr. Philip Starr Dr. Paul
Slide 21: Growing a Strong Base of Clinical Support
Growing a Strong Base of Clinical Support NEUROSURGEON PERSPECTIVE ON CLEARPOINT The ClearPoint System “represents a major step forward = in our ability to treat complex neurological diseases." r. Karl Sillay, former Director of Adult Functional and Stereotactic Neurological Surgery at the Universit
Slide 22: Building a Library of Peer-Reviewed Journal Support
Building a Library of Peer-Reviewed Journal Support SURGERY
Slide 23: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint 23 ClearPoint Sites (21 US, 2 Europe) Taiversity of Wisconsin Hospital and UCSE Medical Center SPECTRUM wears? Uwiealth ry Peon WU iieatte Cake aaa Balti San Francisco Cincinnati Hospital MDAnderson ‘Center Methalist The Methodist SS Hospitar MA coston EMORY As of Ma
Slide 24: Expanding the Reach of the ClearPoint Gateway
Expanding the Reach of the ClearPoint Gateway Expanding the Footprint Increasing Utilization US Metical Center | ae { Hospital Case Study: Initial utilization: 1 case per month Implemented “Immersion Strategy” Current utilization: 6 cases per month Keys to success: High customer touches Trained mult
Slide 25: Increasing Awareness of ClearPoint
Increasing Awareness of ClearPoint HOSPITAL PRESS RELEASES Hackensack University Medical Center First on East Coast to Use MRI-Guided Neurosurgical Procedure to Treat Parkinson's Disease Cutting-Edge Interventional MRI System Transforms Brain Surgery for Parkinson's Patients [DES Operation fr Parkin
Slide 26: Increasing Awareness of ClearPoint
Increasing Awareness of ClearPoint HOSPITAL MARKETING - LOCAL NEWS "MiL Interveritlons tivextor Presentation’
Slide 27: ClearPoint Business is Growing
ClearPoint Business is Growing Growth Indicators - Strong quarterly sequential growth in disposable revenue - Growing number of sites - Additions to Sales and Support team increase capacity to further grow sites/utilization sso js00 jszs0 Js200 aso Jsx00 Disposable Revenue {Amounts in 0003) | 92-201
Slide 28: Expanding ClearPoint Drug Delivery Opportunity
Expanding ClearPoint Drug Delivery Opportunity Involvement in 5 Investigational Drug Trials: 1) 2) 3) 4) 5) "MiL Interveritlons tivextor Presentation’ Toca 511 for GBM (brain tumor) — Multicenter / Tocagen 124I-8H9 Radio Immunotherapy for DIPG (brain tumor) — Memorial Sloan Kettering Cancer Center I
Slide 29: Building the Value of the ClearPoint Gateway
Building the Value of the ClearPoint Gateway Summarizing Progress over Recent Quarters Grown Clinical Support among Neurosurgeons Built Peer-Reviewed Journal Library Expanded ClearPoint Geographic Footprint Increased Utilization, Working to Replicate Case Study Success Increased Marketplace Awarenes
Slide 30: Our Next Platform in Development — ClearTrace
Our Next Platform in Development — ClearTrace ClearTrace™ Cardiac Intervention System for minimally invasive surgical procedures in the heart. Intra-procedural Visualization: Current Procedure vs. ClearTrace Procedure Current Procedure ClearTrace System CAUTION: Investigational device. Limited by fe
Slide 31: Financial Highlights
Financial Highlights TRADING ACTIVITY = Symbol - MRIC (OTCBB) = $1.19 — Closing Price (July 8, 2013) = Average Daily Volume — approx. 100,000 (as of July 8, 2013) BALANCE SHEET HIGHLIGHTS = Cash at March 31 -$9.2M = Shares Outstanding as of March 31 — 57.3M shares (all common) = S80M has been invest
Slide 32: Financial Highlights
Financial Highlights INCOME STATEMENT HIGHLIGHTS = Total product revenues increased 107% Q1 2013 vs. Q1 2012 = Disposable product revenues grew by 128% for the year (2012 vs. 2011) = Strong sequential quarterly growth in recurring disposable revenues Quarters Ended March 31, Years Ended December 31,
Slide 33: Summary
Summary + We are establishing ClearPoint as the Gateway for the Delivery of Neurological Therapies * We believe this Gateway will have tremendous value, driven by millions of neuro disease patients who otherwise have limited therapeutic options * We are making significant commercial progress — prove
Slide 34: MRI Interventions, Inc. contact details
ws. M-I INTERVENTIONS ™ Ticker: MRIC MRI Interventions, Inc. One Commerce Square, Suite 2550 Memphis, TN 38103 (901) 522-9300 info@mriinterventions.com
Slide 35: Descriptions of the Videos Included in this Presentation
Descriptions of the Videos Included in this Presentation This presentation includes five embedded videos. The following table provides the location of each video in the presentation and a description of each video: Slide No. Description This video depicts the target selection and entry planning port
Slide 36: ClearPoint Neuro Intervention System
ClearPoint Neuro Intervention System ClearPoint Draping in Preparation for a Case in a Diagnostic MRI Suite
Slide 37: ClearPoint Neuro Intervention System
ClearPoint Neuro Intervention System Selected ClearPoint Disposable Components "MiL Interveritlons tivextor Presentation’ a7
MRI Interventions — Investor Presentation (July 2013) on 6ix